Comparison of the effectiveness and antibiotic cost among ceftriaxone, ertapenem, and levofloxacin in treatment of community-acquired complicated urinary tract infections  by Lin, Hsin-An et al.
Journal of Microbiology, Immunology and Infection (2016) 49, 237e242Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.e- jmii .comORIGINAL ARTICLEComparison of the effectiveness
and antibiotic cost among ceftriaxone,
ertapenem, and levofloxacin in treatment
of community-acquired complicated urinary
tract infections
Hsin-An Lin a,b, Ya-Sung Yang a, Jing-Xun Wang a,
Hsin-Chung Lin c, De-Yu Lin a, Chun-Hsiang Chiu a,
Kuo-Ming Yeh a, Jung-Chung Lin a,*, Feng-Yee Chang aa Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service
General Hospital, National Defense Medical Center, Taipei, Taiwan
b Department of Internal Medicine, Songshan Branch of Tri-Service General Hospital, National Defense
Medical Center, Taipei, Taiwan
c Division of Clinical Pathology, Department of Pathology, Tri-Service General Hospital, National
Defense Medical Center, Taipei, TaiwanReceived 15 June 2014; received in revised form 15 December 2014; accepted 23 December 2014
Available online 10 January 2015KEYWORDS
ceftriaxone;
community-acquired
urinary tract
infection;
cost effectiveness;
ertapenem;
levofloxacin* Corresponding author. Division of
Hospital, National Defense Medical Ce
E-mail address: linjungchung1@yah
http://dx.doi.org/10.1016/j.jmii.2014
1684-1182/Copyright ª 2015, TaiwanPurpose: To study characteristics of patients with community-acquired complicated urinary
tract infections (cUTIs) and to compare effectiveness and antibiotic cost of treatment with
ceftriaxone (CRO), levofloxacin (LVX), and ertapenem (ETP).
Methods: This retrospective study enrolled patients who had community-acquired cUTIs
admitted to Division of Infectious Diseases in a single medical center from January 2011 to
March 2013. Effectiveness, antibiotic cost, and clinical characteristics were compared among
patients treated with CRO, LVX, and ETP.
Results: There were 358 eligible cases, including 139 who received CRO, 128 treated with ETP,
and 91 with LVX. The most common pathogen was Escherichia coli. The susceptibilities of these
three agents were higher and more superior than first-line antibiotics. Treatment with ETP was
associated with a significantly shorter time to defervescence since admission (CRO: 39 hours,
ETP: 30 hours, and LVX: 38 h; pZ 0.031) and shorter hospitalization stay (CRO: 4 days, ETP: 3Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General
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238 H.-A. Lin et al.days, and LVX: 4 days; p < 0.001). However, the average antibiotic costs in the CRO group were
significantly lower than that in the other two groups [CRO: 62.4 United States dollars (USD),
ETP: 185.33 USD, and LVX: 204.85 USD; p < 0.001].
Conclusion: The resistance of cUTIs isolates to first-line antibiotic is high. Using ETP, CRO, and
LVX in the treatment of cUTIs for good clinical response should be suggested. Among the three
agents, ETP had better susceptibility than CRO and LVX, reached defervescence sooner, and
was associated with shorter hospital stays. However, using CRO in cUTIs was less expensive
than the other two agents.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Urinary tract infections (UTIs) are responsible for approxi-
mately 7 million physician office visits and more than 1
million hospitalizations in the United States each year.1e3
Most of these cases are uncomplicated infections of the
bladder in otherwise healthy young women that are easily
managed with short-term antimicrobial therapy. However,
complicated UTIs (cUTIs) may occur in both sexes and all
age groups and are frequently associated with either
anatomical or functional urinary tract abnormalities.4,5
Treatment of cUTIs is generally less successful because of
the emergence of antimicrobial resistant strains, and such
cases are a significant challenge for clinicians.1,6 Ceftriax-
one (CRO), ertapenem (ETP), and levofloxacin (LVX) are
recommended in the treatment guidelines for cUTIs.4,7,8
Research has compared treatment of cUTIs with CRO and
ETP, with CRO and LVX, but no study has compared the
treatment outcome between CRO, ETP, and LVX.
This study compared treatment outcomes of CRO, ETP,
and LVX and antibiotic costs related to admitted patients
with cUTIs.Methods
Patient population and clinical evaluation
This study used retrospective chart review and was
approved by the Institutional Review Board of the Tri-
Service General Hospital (TSGHIRB Approval Number: 097-
05-28), an 1800-bed medical center in Taipei, Taiwan. All
the patients enrolled were those admitted to Division of
Infection Diseases (ID) with cUTIs during January 2011 to
March 2013.
All patients who received a diagnosis within 48 hours of
admission and in whom health care associated infections
were excluded were considered to have community-
acquired infections. All patients who were at least 18
years old and had cUTIs with acute pyelonephritis (APN)
that required parenteral antibiotic therapy were eligible.
Criteria for APN included fever, flank pain or costovertebral
angle knocking or percussion tenderness, pyuria (10 white
blood cells per high-power field).9 Criteria for cUTIs in
males were symptoms/signs of UTI. Females were addi-
tionally required to have either an indwelling catheter,current bladder catheterization, instrumentation of the
urinary tract, functional or anatomic abnormality of the
urinary tract9 including foreign bodies (e.g., stones,
indwelling catheters or other drainage devices, obstruc-
tion), immunosuppression, renal insufficiency, and comor-
bid illness.4
Individuals with other infections since admission or
during admission who received antibiotics other than the
three study agents, patients with changing treatment reg-
imens during admission, those with different treatment
regimens by the physician of the emergency department,
patients who received surgery during admission, pregnancy
or lactation in women, patients with any rapidly progressive
or terminal disease, or individuals with prior to renal
transplantation were excluded. Patients in whom health
care-associated infections had been diagnosed were
excluded if any of the following criteria were present: >48
hours of hospitalization within the past 90 days, receipt of
hemodialysis, administration of intravenous medication or
home wound care in the past 30 days, or residence in a
nursing home or long-term care facility. Decision regarding
the antibiotic therapy was made by the attending physi-
cians who took care of the patients. The initial antibiotic
regimen was administered after blood and urine samples
had been taken for culture.
Effectiveness and cost variables
The primary outcome was the time to defervescence after
admission was calculated since arrival on the ward, and the
secondary outcome was duration of hospital stay. The
antibiotic cost was also calculated as the sum of all anti-
biotic usage during hospital course.
Bacterial cultures and antimicrobial susceptibility
tests
Fresh urine and blood samples were delivered to the lab-
oratory and were processed according to standard pro-
cedures soon after UTIs were confirmed in the emergency
department or ward. Blood and urine samples were plated
on MacConkey and CPS3 agar and processed using an
automated blood culture system (VITEK 2 complete ID/AST
Automation system; bioMe´rieux, Mercy l’Etoile, France).
Antibiotic susceptibility testing was determined using VITEK
2 complete ID/AST Automation system in accordance with
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M100-S2010 for the following antibiotics: ampicillin, cefa-
zolin, gentamicin, amikacin, ampicillin-sulbactam,
trimethoprim-sulfamethoxazole, piperacillin-tazobactam,
ceftazidime, CRO, imipenem, LVX, cefepime, nitro-
furantoin, and ETP for gram-negative bacteria (GNB). A
difference of at least 5 mm between the zone diameters of
either the cefotaxime or ceftazidime disks and their
respective cephalosporin/clavulanate disks was considered
to be phenotypic confirmation for the production of
extended-spectrum b-lactamase (ESBL) according to the
criteria of the Clinical and Laboratory Standards Institute,
M100-S19.11
Statistical analysis
To assess differences, the Chi-square test with Yates
correction or Fisher’s exact test was used to compare the
discrete variables; the Student t test or ManneWhitney
rank-sum test was used to analyze continuous variables. A p
value <0.05 was considered statistically significant. All the
analyses were processed with SPSS software version 18.0
(SPSS Inc., Chicago, IL, USA).Results
Patient population and clinical evaluation
There were 639 patients admitted to the ward of infectious
diseases (ID) Section under diagnosis of cUTIs from January
2011 to March 2013. A total of 358 patients met our inclu-
sion criteria, including 139 who received CRO, 128 received
ETP, and 91 received LVX (Fig. 1).Figure 1. Flow diagram of complicated urinary tract infecti
CRO Z ceftriaxone; cUTI Z complicated urinary tract infection; EThe demographic and clinical characteristics of the
three groups were shown in Table 1. The most common
underlying disease was hypertension in the three groups
(34.1e50.0%; p Z 0.064). The LVX group had significantly
more patients with flank pain [CRO: 23.0% (32/139), ETP:
29.7% (38/128), LVX: 39.6% (36/91); p Z 0.027]; however,
the CRO group had significantly more patients with chills
[CRO: 59.0% (82/139), ETP: 38.3% (49/128), LVX: 44.0% (40/
91); p Z 0.002].
Effectiveness and cost
The clinical outcomes and antibiotic costs of patients in the
three groups were shown in Table 2. In the ETP group, the
patients had shorter time to defervescence since admission
compared to the other two groups (CRO: 39 hours, ETP: 30
hours, and LVX: 38 hours; p Z 0.031). In the ETP group,
patients also had shorter hospitalization stay (CRO: 4 days,
ETP: 3 days, and LVX: 4 days; p < 0.001). The average
antibiotic costs in CRO group was significantly lower than
that in the other two groups [CRO: 62.4 United States dol-
lars (USD), ETP: 185.33 USD, and LVX: 204.85 USD;
p < 0.001].
Bacterial cultures and antimicrobial susceptibility
tests
There were 208 GNB and 28 gram-positive cocci (GPC) and
two Candida spp. growth in the 358 urine isolates.
Bacteremia was found in 86 patients (28.0%). The most
common GNB pathogens were Escherichia coli, Klebsiella
pneumoniae, and Proteus mirabilis (Fig. 2). Among the 28
isolates of GPC, 17 were Enterococcus spp., six were
Streptococcus spp., and five were Staphylococcus spp. Theons of enrolled participants. AMS Z ampicillin-sulbactam;
TP Z ertapenem; LVX Z levofloxacin.
Table 1 Demographic and clinical characteristics of patients with complicated urinary tract infections
Characteristic Ceftriaxone group
(N Z 139)
Ertapenem group
(N Z 128)
Levofloxacin group
(N Z 91)
p
Mean  SD/n (%)
Mean age (y) 64.49  20.14 67.17  20.78 61.03  16.90 0.075
Sex 0.465
Male 32 (23.0) 38 (29.7) 24 (26.4)
Female 107 (77.0) 90 (70.3) 67 (73.6)
Underlying disease
Hypertension 61 (43.9) 64 (50.0) 31 (34.1) 0.064
Diabetes mellitus 34 (24.5) 31 (24.2) 25 (27.5) 0.837
Chronic liver disease 3 (2.2) 4 (3.1) 1 (1.1) 0.605
chronic renal disease 10 (7.1) 8 (6,2) 6 (6.5) 0.812
Urolithiasisa 12 (8.6) 9 (7.0) 7 (7.7) 0.887
Malignant disorder 13 (9.4) 10 (7.8) 10 (11.0) 0.724
Indwelling urinary catheterb 18 (13.0) 16 (12.5) 4 (4.4) 0.083
Clinical presentations
Fever 121 (87.0) 109 (85.1) 78 (85.7) 0.843
Dysuria 38 (27.3) 39 (30.5) 33 (36.3) 0.356
Frequency 34 (24.5) 25 (19.5) 30 (33.0) 0.076
Flank pain 32 (23.0) 38 (29.7) 36 (39.6) 0.027
Chills 82 (59.0) 49 (38.3) 40 (44.0) 0.002
Microorganism
ESBL-producing strainsc 2 (1.4) 6 (4.7) 1 (1.1) 0.145
a Including renal stone, ureteral stone, bladder stone.
b Including percutaneous nephrostomy, suprapubic catheter, and Foley catheter.
c ESBL Z extended-spectrum b-lactamase; SD Z standard deviation.
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lates were shown in Table 3. The most effective antibiotics
were amikacin, imipenem, and ETP (98.1e100%), followed
by cefepime, ceftazidime, and CRO (93.8e95.7%). The
susceptibility to b-lactam agents ranged from 60.3% to
99.5% and the susceptibility to LVX was 87.0%. The sus-
ceptibility to LVX was significantly lower than ETP and CRO
(87.0%, 98.1%, and 93.8%, respectively, p < 0.001). The
first-generation cephalosporin, ampicillin, trimethoprim-
sulfamethoxazole, and ampicillin-sulbactam have lower
susceptibilities (0.5e60.3%). ESBL strains were few among
the isolates (9/208, 4.3%). There were no statistical dif-
ferences among the three groups in their antimicrobial
susceptibilities.Table 2 Clinical outcomes and antibiotic cost of patients with
Ceftriaxone group
(N Z 139)
Median (Q1eQ3)/n (%)
Time to defervescence since admission (h)a 39 (19e74)
Hospital day (day) 4 (4e6)
Antibiotic cost (USD) 62.4 (62.4e78)
Mortality during admission 0 (0.0)
a Time to defervescence since admission was calculated since arriv
USD Z United States dollars.Discussion
The study compared the clinical characteristics and anti-
biotic costs in patients with cUTIs receiving three different
antibiotics. Compared to patients in the other two groups,
ETP group had shorter time to defervescence since admis-
sion and shorter hospitalization stay. The antibiotic cost
was significant lower in CRO group. E. coli, K. pneumoniae,
and P. mirabilis still were the most frequent encountered
pathogens in the current study. The antimicrobial suscep-
tibilities were generally good in the three agents, but poor
in cefazolin, ampicillin, trimethoprim-sulfamethoxazole,
and ampicillin-sulbactam.complicated urinary tract infections
Ertapenem group
(N Z 128)
Levofloxacin group
(N Z 91)
p
30 (4.5e59.5) 38 (9e64) 0.03
3 (3e5) 4 (3e6) <0.01
185.33 (139e231.67) 204.85 (204.85e256.06) <0.01
0 (0.0) 0 (0.0) e
ed to ward.
Figure 2. Bacterial species and isolate numbers of 208 iso-
lates causing complicated urinary tract infections.
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ogen in cUTIs, especially E. coli, K. pneumoniae, and P.
mirabilis. Compared to our previous study 10 years ago,12
the isolates in the current study showed lower suscepti-
bility to first-line antibiotics. This result suggested that for
the increasing antimicrobial resistances in community-
acquired cUTIs, empirical antimicrobial treatment should
be carefully decided.
Our results showed that ETP was more effective than CRO
or LVX in defervescence and having shorter hospitalization.
It has previous been described that ETP was more active
against the enteric gram-negative pathogens than ceftriax-
one and piperacillinetazobactam.13 Even though there was
no statistical difference in antimicrobial susceptibilities
among the three drugs, the isolates had higher susceptibilityTable 3 The antimicrobial susceptibilities of 208 gram-negative
Ceftriaxone group
(91/139; 65.4%)
Ertapenem group
(73/128; 57%)
N (%)
AM 30 (33.7) 16 (22.5)
CZ 0 (0.0) 1 (1.4)
GM 80 (87.9) 62 (84.9)
AN 91 (100.0) 73 (100.0)
AMS 54 (60.7) 39 (54.9)
SXT 53 (59.6) 36 (50.7)
TZP 84 (92.3) 68 (93.2)
CAZ 87 (95.6) 67 (91.8)
CRO 87 (95.6) 65 (89.0)
IPM 91 (100.0) 72 (98.6)
LVX 82 (90.1) 58 (79.5)
FEP 89 (97.8) 67 (91.8)
F/M 77 (86.5) 60 (84.5)
ETP 89 (97.8) 71 (97.3)
AM Z ampicillin; AMS Z ampicillin-sulbactam; AN Z amikacin;
ETP Z ertapenem; F/M Z nitrofurantoin; GM Z gentamycin; IPM Z
oxazole; TZP Z piperacillin-tazobactam.to ETP. This may also explain why patients in the ETP group
had a better response. In addition, CRO and ETP have
excellent pharmacokinetics presenting higher blood and
urine concentrations above minimum inhibitory concentra-
tions than LVX.14e17 Another important issue was the generic
formulations of CRO. During the study period, there were
many generic formulations of CRO available in Taiwan (and
in our hospital). The generic CROs accounted for more than
half of the clinical prescriptions of all CROs in our hospital.18
It might also play a role in the clinical outcomes.
There is an increase of fluoroquinolone resistance in
GNBs worldwide.19,20 Bouchillon et al21 reported that flu-
oroquinolone resistance rates varied widely among
different countries (6e75%). The isolates from our study
had an average LVX susceptibility rate of 87.0%. Lu et al22
reported that the percentage of ESBL-producers was 28.2%
among all UTI pathogens in the Asia-Pacific region, and in
Taiwan they were 15% and 27% in E. coli and K. pneumoniae
isolates. In contrast to CRO and LVX, ETP showed excellent
activity against ESBL-producing strains and even those are
resistant to b-lactam/b-lactamase inhibitor combination
agents.23e25
This study is subject to several limitations regularly
found in retrospective studies. Several confounding factors
could not be well controlled in the three groups, such as the
decisions of antibiotic selection cannot be well controlled
among patients, and the styles of patient care were also
varied among different doctors. However, our sample size
was relatively big and the patient characteristics between
groups were similar. A well-conducted prospective study
may be necessary in the future to elucidate the differences
in treating cUTIs among the three agents.
In conclusion, the resistance of cUTIs isolates to first-line
antibiotics is high. ETP, CRO, and LVX in the treatment of
cUTIs had good clinical response. Among the three agents,
ETP had better susceptibility than CRO and LVX, reached
defervescence sooner, and was associated with shorterisolates causing complicated urinary tract infections
Levofloxacin group
(44/91; 48.3%)
Total (N Z 208) p
17 (38.6) 63 (30.9) 0.236
0 (0.0) 1 (0.5) 0.600
40 (90.9) 182 (87.5) 0.654
44 (100.0) 208 (100.0) e
30 (68.2) 123 (60.3) 0.545
21 (47.7) 110 (53.9) 0.348
42 (95.5) 194 (93.3) 0.916
43 (97.7) 197 (94.7) 0.157
43 (97.7) 195 (93.8) 0.106
44 (100.0) 207 (99.5) 0.395
41 (93.2) 181 (87.0) 0.144
43 (97.7) 199 (95.7) 0.128
38 (86.4) 175 (85.8) 0.326
44 (100.0) 204 (98.1) e
CAZ Z ceftazidime; CRO Z ceftriaxone; CZ Z cefazolin;
imipenem; LVX Z levofloxacin; SXT Z trimethoprim-sulfameth-
242 H.-A. Lin et al.hospital stays. However, using CRO in cUTIs was less expen-
sive than the other two agents.Conflict of interest
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